Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$14995

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Report Overview

The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was $39.2 billion in 2023. The GLP-1R agonists in the type 2 diabetes and obesity market will witness significant growth during the forecast period.

GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion)

GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion)

Buy the Full Report to Know More about the GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Forecast

Download a Free Report Sample

The Glucagon-Like Peptide-1 Receptor (GLP-1R) agonists in the type 2 diabetes and obesity market report covers 68 geographical markets and provides a forecast model for the market through 2033. This report contains sales forecast extrapolations for the 7 major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) and an additional 61 geographical markets (61M), totaling 68 markets (68M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare and POLI Price Intelligence databases.

Market Size (2023) $39.2 Billion
Key Countries ·       Africa

·       APAC

·       Europe

·       LATAM

·       Middle East

·       North America

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Segmentation by Regions

North America accounted for the highest GLP-1R Agonists in the Type 2 Diabetes and Obesity market share in 2023.

 The key regions in the GLP-1R agonists in the type 2 diabetes and obesity market are Africa, APAC, Europe, LATAM, the Middle East, and North America. APAC and Europe also had a significant share of the GLP-1R agonists in the type 2 diabetes and obesity market.

GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Analysis by Regions, 2023 (%)

GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Analysis by Regions, 2023 (%)

Buy the Full Report for More Country Insights into the GLP-1R Agonists in the Type 2 Diabetes and Obesity Market

Download a Free Report Sample

Key 7MM Events Driving the 68M Forecast Extrapolation

A few of the key events occurring in the 7MM that drive the trajectory of the 68M forecast for GLP-1R agonists in the type 2 diabetes and obesity markets between 2023 and 2033 are Saxenda Patent Expiry, Victoza Patent Expiry, Suliqua Patent Expiry, and Victoza Patent Expiry among others.

GLP-1R Agonists in the Type 2 Diabetes and Obesity Regional Outlook (Value, $ Billion, 2023-2033)

  • Africa
  • APAC
  • Europe
  • LATAM
  • Middle East
  • North America

Scope

This publication is an expanded version of the Excel model containing the patient-based forecast sales for Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity, covered in GlobalData’s report “Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Seven -Market Drug Forecast and Market Analysis”, published in April 2024. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in the Type 2 Diabetes and Obesity therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Regeneron
Bayer
Roche
Novartis
AbbVie
RegenxBio
Outlook Therapeutics
Kodiak Sciences
Opthea
Apellis Pharmaceuticals
Iveric Bio
Genentech
Chugai
Bausch + Lomb
Clinigen
Cheplapharm
Ribomic
Unity Biotechnology
Clearside Biomedical
EyePoint Pharmaceuticals
Ocular Therapeutix
Ashvattha Therapeutics
Outlook Therapeutics
Adverum Biotechnlologies
Formycon
Essex Bio
Xbrane Biopharma
Celltrion
Lupin
Viatris
Amgen
Samsung Bioepis
Senju
SamChunDang Pharm Co Ltd

Table of Contents

  • 1. About GlobalData
  • 2. List of Contents

    • 2.1. List of Tables
    • 2.2. List of Figures

  • 3. Executive Summary

    • 3.1. Overview
    • 3.2. 68M summary statistics
    • 3.3. Key 7MM events driving the 68M forecast extrapolation.

  • 4. Appendix

    • 4.1. Abbreviations
    • 4.2. Methodology

      • 4.2.1. Patient-based forecast methodology
      • 4.2.2. 68M forecast extrapolation methodology.

    • 4.3. Primary research – key opinion leaders interviewed for this report.
    • 4.4. Primary research – prescriber survey
    • 4.5. About the authors

      • 4.5.1. Analyst
      • 4.5.2. Therapy area directors
      • 4.5.3. Epidemiologist
      • 4.5.4. Epidemiology reviewers
      • 4.5.5. Vice President of Disease Intelligence and Epidemiology
      • 4.5.6. Global Head and EVP of Healthcare Operations and Strategy

  • 5. Contact Us

Frequently asked questions

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 standard reports
Currency USD
$14,995

Can be used by individual purchaser only

$44,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 in real time.

  • Access a live Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.